A review of the latest and most pertinent information from EULAR 2021 regarding COVID-19 for patients with rheumatic musculoskeletal diseases. This includes an overview of the topic, from an assessment of the safety profile of vaccines, to the impact of biologic or targeted synthetic disease-modifying anti-rheumatic drug treatment on COVID-19 outcomes. The discussion then shifts to a review of research presented at EULAR 2021 examining the promise demonstrated in clinical trials for small molecule JAK1 inhibitors in the treatment of patients with ankylosing spondylitis. Furthermore, the episode features an expert analysis of how drugs traditionally used to treat RA have been repurposed to battle the COVID-19 pandemic.
This podcast is supported by Janssen Pharmaceutical Companies of Johnson & Johnson. The views expressed in this podcast are those of the individual speaker and do not necessarily reflect the views of Janssen Pharmaceutical Companies of Johnson & Johnson.